Autologous co-culture of primary human alveolar macrophages and epithelial cells for investigating aerosol medicines. Part II: evaluation of IL-10-loaded microparticles for the treatment of lung inflammation.
dc.contributor.author | Hittinger, Marius | |
dc.contributor.author | Mell, Nico Alexander | |
dc.contributor.author | Huwer, Hanno | |
dc.contributor.author | Loretz, Brigitta | |
dc.contributor.author | Schneider-Daum, Nicole | |
dc.contributor.author | Lehr, Claus Michael | |
dc.date.accessioned | 2016-11-15T13:09:07Z | |
dc.date.available | 2016-11-15T13:09:07Z | |
dc.date.issued | 2016-09 | |
dc.identifier.citation | Autologous co-culture of primary human alveolar macrophages and epithelial cells for investigating aerosol medicines. Part II: evaluation of IL-10-loaded microparticles for the treatment of lung inflammation. 2016, 44 (4):349-360 Altern Lab Anim | en |
dc.identifier.issn | 0261-1929 | |
dc.identifier.pmid | 27685186 | |
dc.identifier.uri | http://hdl.handle.net/10033/620580 | |
dc.description.abstract | Acute respiratory distress syndrome is linked to inflammatory processes in the human lung. The aim of this study was to mimic in vitro the treatment of lung inflammation by using a cell-based human autologous co-culture model. As a potential trial medication, we developed a pulmonary dry powder formulation loaded with interleukin-10 (IL-10), a potent anti-inflammatory cytokine. The inflammatory immune response was stimulated by lipopolysaccharide. The co-culture was combined with the Pharmaceutical Aerosol Deposition Device on Cell Cultures )PADDOCC), to deposit the IL-10-loaded microparticles on the inflamed co-culture model at the air-liquid interface. This treatment significantly reduced the secretion of interleukin-6 and tumour necrosis factor, as compared to the deposition of placebo (unloaded) particles. Our results show that the alveolar co-culture model, in combination with a deposition device such as the PADDOCC, may serve as a powerful tool for testing the safety and efficacy of dry powder formulations for pulmonary drug delivery. | |
dc.language | ENG | |
dc.language.iso | en | en |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.title | Autologous co-culture of primary human alveolar macrophages and epithelial cells for investigating aerosol medicines. Part II: evaluation of IL-10-loaded microparticles for the treatment of lung inflammation. | en |
dc.type | Article | en |
dc.contributor.department | Helmholtz-Institute for Pharmaceutical Research Saarland,Universitätscampus E8.1, 66123 Saarbrücken, Germany. | en |
dc.identifier.journal | Alternatives to laboratory animals : ATLA | en |
refterms.dateFOA | 2018-06-12T22:02:58Z | |
html.description.abstract | Acute respiratory distress syndrome is linked to inflammatory processes in the human lung. The aim of this study was to mimic in vitro the treatment of lung inflammation by using a cell-based human autologous co-culture model. As a potential trial medication, we developed a pulmonary dry powder formulation loaded with interleukin-10 (IL-10), a potent anti-inflammatory cytokine. The inflammatory immune response was stimulated by lipopolysaccharide. The co-culture was combined with the Pharmaceutical Aerosol Deposition Device on Cell Cultures )PADDOCC), to deposit the IL-10-loaded microparticles on the inflamed co-culture model at the air-liquid interface. This treatment significantly reduced the secretion of interleukin-6 and tumour necrosis factor, as compared to the deposition of placebo (unloaded) particles. Our results show that the alveolar co-culture model, in combination with a deposition device such as the PADDOCC, may serve as a powerful tool for testing the safety and efficacy of dry powder formulations for pulmonary drug delivery. |